CN116419754A - 用于治疗和预防肺部感染的葡萄糖苷酶抑制剂 - Google Patents

用于治疗和预防肺部感染的葡萄糖苷酶抑制剂 Download PDF

Info

Publication number
CN116419754A
CN116419754A CN202180072511.2A CN202180072511A CN116419754A CN 116419754 A CN116419754 A CN 116419754A CN 202180072511 A CN202180072511 A CN 202180072511A CN 116419754 A CN116419754 A CN 116419754A
Authority
CN
China
Prior art keywords
group
substituted
alkyl
optionally substituted
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180072511.2A
Other languages
English (en)
Chinese (zh)
Inventor
塞巴斯蒂安·马里奥·马尔库乔
大卫·亚历山大·沃登·莫顿
西门·彼得·图克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keweilix Medical Co ltd
Original Assignee
Keweilix Medical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020903051A external-priority patent/AU2020903051A0/en
Application filed by Keweilix Medical Co ltd filed Critical Keweilix Medical Co ltd
Publication of CN116419754A publication Critical patent/CN116419754A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN202180072511.2A 2020-08-26 2021-08-25 用于治疗和预防肺部感染的葡萄糖苷酶抑制剂 Pending CN116419754A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020903051 2020-08-26
AU2020903051A AU2020903051A0 (en) 2020-08-26 Compounds, compositions and uses thereof
PCT/AU2021/050978 WO2022040741A1 (en) 2020-08-26 2021-08-25 Glucosidase inhibitors for the treatment and prevention of pulmonary infections

Publications (1)

Publication Number Publication Date
CN116419754A true CN116419754A (zh) 2023-07-11

Family

ID=80352192

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180072511.2A Pending CN116419754A (zh) 2020-08-26 2021-08-25 用于治疗和预防肺部感染的葡萄糖苷酶抑制剂

Country Status (6)

Country Link
US (1) US20240016786A1 (cg-RX-API-DMAC7.html)
EP (1) EP4203954A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023540259A (cg-RX-API-DMAC7.html)
CN (1) CN116419754A (cg-RX-API-DMAC7.html)
AU (1) AU2021332085B2 (cg-RX-API-DMAC7.html)
WO (1) WO2022040741A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119841765A (zh) * 2025-01-09 2025-04-18 中南大学 Dnj衍生物、药物组合物及其应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202100027464A1 (it) * 2021-10-26 2023-04-26 Univ Degli Studi Di Camerino Composizione comprendente iminozuccheri e/o anisodamina per il trattamento di infezioni virali
US12569473B2 (en) * 2022-07-05 2026-03-10 60 Degrees Pharmaceuticals, Inc. Methods to treat respiratory infection utilizing castanospermine analogs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017192599A1 (en) * 2016-05-02 2017-11-09 Florida State University Research Foundation, Inc. Treatment of zika virus infections using alpha-glucosidase inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1876095A (en) * 1994-02-25 1995-09-11 G.D. Searle & Co. Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus
GB0116643D0 (en) * 2001-07-09 2001-08-29 Virogen Ltd Antiviral compounds
FR2861991B1 (fr) * 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
WO2011095772A2 (en) * 2010-02-04 2011-08-11 Summit Corporation Plc Novel iminosugar therapeutics
RS58456B1 (sr) * 2011-08-01 2019-04-30 Univ Monash Postupak i formulacije za inhalaciju
EP3934688A4 (en) * 2019-03-08 2022-12-21 University of Virginia Patent Foundation COMPOSITIONS AND METHODS FOR MODULATION OF VIRAL INFECTION THROUGH REGULATION OF GLUCOSYLCERAMIDS
EP4106752A4 (en) * 2020-02-21 2024-03-20 Florida State University Research Foundation, Inc. TREATMENT OF HUMAN CORONAVIRUS INFECTIONS USING ALPHA-GLUCOSIDASE-GLYCOPROTEIN PROCESSING INHIBITORS
US10980756B1 (en) * 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
CN113425720A (zh) * 2020-04-03 2021-09-24 深圳前海诺贝尔奖科学家技术转移转化有限公司 亚胺糖化合物在制备抗SARS-CoV-2病毒的药物中的用途
US20230270826A1 (en) * 2020-07-30 2023-08-31 Delta 4 Gmbh Antiviral use of liraglutide and gefitinib

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017192599A1 (en) * 2016-05-02 2017-11-09 Florida State University Research Foundation, Inc. Treatment of zika virus infections using alpha-glucosidase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HOLWERDA M等: "Identification of five antiviral compounds from the Pandemic Response Box targeting SARS-CoV-2", BIORXIV, 17 May 2020 (2020-05-17), pages 1, XP055908488, DOI: 10.1101/2020.05.17.100404 *
RAJASEKHARAN S.等: "Repurposing of Miglustat to inhibit the coronavirus Severe Acquired Respiratory Syndrome SARS-CoV-2", BIORXIV, 18 May 2020 (2020-05-18), pages 1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119841765A (zh) * 2025-01-09 2025-04-18 中南大学 Dnj衍生物、药物组合物及其应用

Also Published As

Publication number Publication date
WO2022040741A1 (en) 2022-03-03
AU2021332085A1 (en) 2022-05-19
US20240016786A1 (en) 2024-01-18
JP2023540259A (ja) 2023-09-22
AU2021332085B2 (en) 2022-12-08
EP4203954A4 (en) 2025-01-01
EP4203954A1 (en) 2023-07-05

Similar Documents

Publication Publication Date Title
JP7482250B2 (ja) 1’-シアノ置換カルバヌクレオシド類似体の吸入製剤
KR102906597B1 (ko) 흡입형 닌테다닙 및 닌테다닙 염의 특수 제형 조성물
JP2024028720A (ja) エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
JP6021117B2 (ja) エアロゾルのピルフェニドンおよびピリドンアナログの化合物、および、その使用
TWI564295B (zh) 3,5-二胺基-6-氯-n-(n-(4-(4-(2-(己基(2,3,4,5,6-五羥基己基)胺基)乙氧基)苯基)丁基)甲脒基)吡-2-甲醯胺
DK2739268T3 (en) PROCEDURE AND FORMULATION FOR INHALATION
AU2021332085B2 (en) Glucosidase inhibitors for the treatment and prevention of pulmonary infections
JP2018172402A (ja) エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
TW200938232A (en) Novel dosage and formulation
JP2014525471A (ja) 咳および咳発作の治療
JP6919093B2 (ja) 配合物の安定性を高めるために噴霧乾燥によって得られる少なくとも1種の乾燥粉末を含む組成物
CN117615765A (zh) 用ALK-5(TGFβR1)抑制剂治疗肺部疾病的方法
JP2022512208A (ja) ベダキリンの組成物、それらを含む組み合わせ、それらを調製するための方法、それらを含む使用及び治療方法
US20190282543A1 (en) Preparation of Respirable Zafirlukast Particles
US20220378727A1 (en) Dry powder formulations of tamibarotene for pulmonary and intranasal delivery
US20240041805A1 (en) Pharmaceutical compositions of niclosamide and a protein
HK40096612A (en) Glucosidase inhibitors for the treatment and prevention of pulmonary infections
CN107205958A (zh) 包含福莫特罗和布地奈德的药物组合物
HK40084723B (en) Inhalation formulations of 1’-cyano substituted carbanucleoside analogs

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40096612

Country of ref document: HK